# Capecitabine in Low Risk Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct06787339/  
OnCo record `nct06787339` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

Capecitabine in Low Risk Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06787339 by Fudan University, with a registry enrolment figure of 198 participants, started 2025-01-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Capecitabine. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically documented TNBC after early breast cancer surgery (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: Calorite
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06787339
- Phase: 2
- Setting: A Prospective, Single-arm,Clinical Trial Exploring the Efficacy and Safety of Chemotherapy De-escalation Using Capecitabine in Low-risk Early Triple-negative Breast Cancer
- Sponsor: Fudan University
- Enrolled: 198

## Sources

- ClinicalTrials.gov NCT06787339: https://clinicaltrials.gov/study/NCT06787339

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06787339.json